<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10231">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680914</url>
  </required_header>
  <id_info>
    <org_study_id>110808</org_study_id>
    <nct_id>NCT00680914</nct_id>
  </id_info>
  <brief_title>Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™</brief_title>
  <official_title>Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A or Prevenar™ Co-administered With Hiberix™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:

      To demonstrate the immunogenicity in terms of antibody response following primary
      vaccination of Korean infants with the pneumococcal conjugate vaccine GSK 1024850A compared
      to Prevenar™ when co-administered with a Haemophilus influenzae type b (Hib) vaccine in
      children during the first 6 months of life.

      To evaluate the safety/reactogenicity in terms of solicited and unsolicited symptoms and
      serious adverse events following primary vaccination of Korean infants with the pneumococcal
      conjugate vaccine GSK 1024850A.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccination course at 2, 4, 6 months of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects With Vaccine Pneumococcal Serotypes Antibody Concentrations Above the Cut-Off Value</measure>
    <time_frame>One month after administration of 3rd dose of the pneumococcal conjugate vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-pneumococcal antibody cut-off value assessed was 0.20 microgram per milliliter (ug/mL).
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Seropositivity Status Against Protein D and Defined Pneumococcal Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seropositivity status for protein D is defined as anti protein D (anti-PD) antibody concentrations &gt;= 100 Enzyme-Linked Immuno Sorbent Assay (EL) units EL.U/mL.
Seropositivity status for pneumococcal serotypes is defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations &gt;= 0.05 ug/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes Contained in the Vaccine Above the Cut-off Value</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>The results were presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. In this assay the cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was &gt;= 8.
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-pneumococcal antibody cut-off value assessed was 0.20 microgram per milliliter (ug/mL).
Pneumococcal cross-reactive serotypes were 6A and 19A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Pneumococal Serotypes Contained in the Vaccine</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations are reported as Geometric Mean Concentrations in ug/mL. Pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PD Antibody Concentration</measure>
    <time_frame>One month after administration of 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentration of anti-PD antibody given as GMC expressed in EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentration of cross-reactive pneumococcal serotypes 6A and 19A in ug/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>The results were presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. In this assay the cut-off value for opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A was defined as &gt;= 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentration of anti-PRP antibody given as GMC in ug/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Seroprotection Status Against PRP</measure>
    <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection status is defined as anti-PRP antibody concentrations above 0.15 ug/mL and above 1.0 ug/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>Within 4 days after each vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms</measure>
    <time_frame>Within 4 days after each vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed include drowsiness, fever, irritability and loss of appetite.
Fever was defined as axillary temperature &gt;= 37.5 degrees Celsius.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events</measure>
    <time_frame>Within 31 days after each vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAE)</measure>
    <time_frame>Following the administration of the first dose of the study vaccines throughout the entire study period up to study month 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>An SAE is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">503</enrollment>
  <condition>Pneumococcal Disease</condition>
  <condition>Streptococcus Pneumoniae Vaccines</condition>
  <arm_group>
    <arm_group_label>Synflorix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevenar Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine GSK1024850A (Synflorix)</intervention_name>
    <description>3 doses administered intramuscularly.</description>
    <arm_group_label>Synflorix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar</intervention_name>
    <description>3 doses administered intramuscularly.</description>
    <arm_group_label>Prevenar Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Hiberix™</intervention_name>
    <description>3 doses administered intramuscularly.</description>
    <arm_group_label>Prevenar Group</arm_group_label>
    <arm_group_label>Synflorix Group</arm_group_label>
    <other_name>Hib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between, and including 6-12 weeks of age at the time of the
             first vaccination.

          -  Subjects for whom the investigator believes that their parent(s)/guardian(s) can and
             will comply with the requirements of the protocol should be enrolled in the study.

          -  Written and signed informed consent obtained from the parent(s)/guardian(s) of the
             child/ward.

          -  Free of any known or suspected health problems as established by medical history and
             clinical examination before entering into the study.

          -  Born after a gestation period of 36 to 42 weeks inclusive, with a birth weight of at
             least 2.5 kilogram.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days preceding the first dose of the study vaccines, or
             planned use during the study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             birth.

          -  Planned administration/administration of a vaccine not allowed by the study protocol
             during the study period. Vaccines included in the Korean routine immunization
             schedule can be administered at least one week before or at least one month after the
             administration of the study vaccines. Recommended live vaccines not included in the
             Korean routine immunization schedule can be given at least one month before or at
             least one month after the administration of the study vaccines.

          -  A family history of congenital or hereditary immunodeficiency.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period (Hepatitis B immunoglobulins at birth are
             allowed).

          -  Previous vaccination against Streptococcus pneumoniae and/or Haemophilus influenzae
             type b.

          -  History of, or intercurrent Streptococcus pneumoniae and/or Haemophilus influenzae
             type b disease.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  History of any neurological disorders or seizures.

          -  Major congenital defects or serious chronic illness.

          -  Acute disease at the time of enrolment. Study entry should be delayed until the
             illness has improved.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ansan</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucheon-si,</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeongnam</city>
        <zip>641-560</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iksan</city>
        <zip>570-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jeju</city>
        <zip>690-716</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jeonju Jeonbuk</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwon City</city>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wonju-si Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Schuerman L et al. Population variability of opsonophagocytic activity following 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate (PHiD-CV) vaccination more limited than antibody responses. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <reference>
    <citation>Schuerman L et al. Immune responses against cross-reactive pneumococcal serotypes 6A and 19A with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <reference>
    <citation>Kim KH et al. Immunogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Korean infants. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <reference>
    <citation>Schuerman L et al. OPA assay is more reliable predictor of vaccine effectiveness against invasive pneumococcal disease (IPD) than ELISA antibody measurements. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <reference>
    <citation>Kim CH et al. Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Korean children. Abstract presented at the Korean Society of Pediatric Infectious Diseases - 2011 Spring Conference. Seoul, South Korea, 7-11 June 2011.</citation>
  </reference>
  <reference>
    <citation>Kim JS et al. Safety and reactogenicity of primary vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Korean infants. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <reference>
    <citation>Kim CH et al. Immunogenicity of a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) and co-administered vaccines following primary vaccination in Asian infants. Abstract presented at the 5th Asian Congress of Pediatric Infectious Diseases (ACPID). Taipei, Taiwan, 23-26 September 2010.</citation>
  </reference>
  <reference>
    <citation>Schuerman L et al. Population variability in antibody responses following pneumococcal conjugate vaccination: experience with the non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <verification_date>March 2011</verification_date>
  <lastchanged_date>January 12, 2012</lastchanged_date>
  <firstreceived_date>May 16, 2008</firstreceived_date>
  <firstreceived_results_date>May 13, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>pneumococcal conjugate vaccine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Synflorix Group</title>
          <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
        </group>
        <group group_id="P2">
          <title>Prevenar Group</title>
          <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="374"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Consent withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>serious adverse event (SAE)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synflorix Group</title>
          <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
        </group>
        <group group_id="B2">
          <title>Prevenar Group</title>
          <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="374"/>
                <measurement group_id="B2" value="129"/>
                <measurement group_id="B3" value="503"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="9.5" spread="1.49"/>
                <measurement group_id="B2" value="9.5" spread="1.43"/>
                <measurement group_id="B3" value="9.5" spread="1.47"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="189"/>
                <measurement group_id="B2" value="71"/>
                <measurement group_id="B3" value="260"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="185"/>
                <measurement group_id="B2" value="58"/>
                <measurement group_id="B3" value="243"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>East Asia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="373"/>
                <measurement group_id="B2" value="129"/>
                <measurement group_id="B3" value="502"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Southeast Asia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Vaccine Pneumococcal Serotypes Antibody Concentrations Above the Cut-Off Value</title>
        <description>Anti-pneumococcal antibody cut-off value assessed was 0.20 microgram per milliliter (ug/mL).
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
        <time_frame>One month after administration of 3rd dose of the pneumococcal conjugate vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Vaccine Pneumococcal Serotypes Antibody Concentrations Above the Cut-Off Value</title>
            <description>Anti-pneumococcal antibody cut-off value assessed was 0.20 microgram per milliliter (ug/mL).
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="343"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-6B</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="318"/>
                  <measurement group_id="O2" value="121"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-7F</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-9V</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="343"/>
                  <measurement group_id="O2" value="122"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-14</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="342"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-18C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="343"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-19F</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="340"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-23F</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="331"/>
                  <measurement group_id="O2" value="121"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Seropositivity Status Against Protein D and Defined Pneumococcal Serotypes</title>
        <description>Seropositivity status for protein D is defined as anti protein D (anti-PD) antibody concentrations &gt;= 100 Enzyme-Linked Immuno Sorbent Assay (EL) units EL.U/mL.
Seropositivity status for pneumococcal serotypes is defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations &gt;= 0.05 ug/mL.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With a Seropositivity Status Against Protein D and Defined Pneumococcal Serotypes</title>
            <description>Seropositivity status for protein D is defined as anti protein D (anti-PD) antibody concentrations &gt;= 100 Enzyme-Linked Immuno Sorbent Assay (EL) units EL.U/mL.
Seropositivity status for pneumococcal serotypes is defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations &gt;= 0.05 ug/mL.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-PD</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="343"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-6B</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="337"/>
                  <measurement group_id="O2" value="122"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-7F</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-9V</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="343"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-14</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-18C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-19F</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-23F</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="340"/>
                  <measurement group_id="O2" value="122"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes Contained in the Vaccine Above the Cut-off Value</title>
        <description>The results were presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. In this assay the cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was &gt;= 8.
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="165"/>
                  <measurement group_id="O2" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes Contained in the Vaccine Above the Cut-off Value</title>
            <description>The results were presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. In this assay the cut-off value for opsonophagocytic activity against pneumococcal antibody assessed was &gt;= 8.
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Opsono-1 (N=162; 62)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-4 (N=161; 63)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="158"/>
                  <measurement group_id="O2" value="63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-5 (N=165; 62)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="161"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-6B (N=162; 63)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="152"/>
                  <measurement group_id="O2" value="63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-7F (N=164; 59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="164"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-9V (N= 165; 63)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="164"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-14 (N= 165; 63)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="163"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-18C (N= 159; 63)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                  <measurement group_id="O2" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-19F (N=164; 61)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="159"/>
                  <measurement group_id="O2" value="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-23F (N= 164; 63)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="160"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value</title>
        <description>Anti-pneumococcal antibody cut-off value assessed was 0.20 microgram per milliliter (ug/mL).
Pneumococcal cross-reactive serotypes were 6A and 19A.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Cross-reactive Pneumococcal Serotype Antibody Concentrations Above the Cut-Off Value</title>
            <description>Anti-pneumococcal antibody cut-off value assessed was 0.20 microgram per milliliter (ug/mL).
Pneumococcal cross-reactive serotypes were 6A and 19A.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-6A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="232"/>
                  <measurement group_id="O2" value="85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-19A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Pneumococal Serotypes Contained in the Vaccine</title>
        <description>Concentrations are reported as Geometric Mean Concentrations in ug/mL. Pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Antibody Concentrations Against Pneumococal Serotypes Contained in the Vaccine</title>
            <description>Concentrations are reported as Geometric Mean Concentrations in ug/mL. Pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.</description>
            <units>ug/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.41" lower_limit="3.14" upper_limit="3.71"/>
                  <measurement group_id="O2" value="0.04" lower_limit="0.04" upper_limit="0.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.00" lower_limit="3.67" upper_limit="4.35"/>
                  <measurement group_id="O2" value="5.35" lower_limit="4.66" upper_limit="6.15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.52" lower_limit="4.24" upper_limit="4.83"/>
                  <measurement group_id="O2" value="0.07" lower_limit="0.06" upper_limit="0.08"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-6B</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.40" lower_limit="1.24" upper_limit="1.58"/>
                  <measurement group_id="O2" value="2.07" lower_limit="1.75" upper_limit="2.44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-7F</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.08" lower_limit="3.77" upper_limit="4.41"/>
                  <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-9V</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.39" lower_limit="3.09" upper_limit="3.71"/>
                  <measurement group_id="O2" value="5.09" lower_limit="4.34" upper_limit="5.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-14</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.54" lower_limit="5.02" upper_limit="6.12"/>
                  <measurement group_id="O2" value="8.51" lower_limit="7.27" upper_limit="9.95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-18C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.80" lower_limit="5.17" upper_limit="6.52"/>
                  <measurement group_id="O2" value="5.13" lower_limit="4.31" upper_limit="6.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-19F</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.41" lower_limit="6.67" upper_limit="8.23"/>
                  <measurement group_id="O2" value="2.77" lower_limit="2.45" upper_limit="3.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-23F</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.96" lower_limit="1.75" upper_limit="2.19"/>
                  <measurement group_id="O2" value="3.94" lower_limit="3.26" upper_limit="4.77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PD Antibody Concentration</title>
        <description>Concentration of anti-PD antibody given as GMC expressed in EL.U/mL.</description>
        <time_frame>One month after administration of 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-PD Antibody Concentration</title>
            <description>Concentration of anti-PD antibody given as GMC expressed in EL.U/mL.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1622.4" lower_limit="1500.8" upper_limit="1754.0"/>
                  <measurement group_id="O2" value="88.2" lower_limit="74.7" upper_limit="104.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes</title>
        <description>Concentration of cross-reactive pneumococcal serotypes 6A and 19A in ug/mL.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes</title>
            <description>Concentration of cross-reactive pneumococcal serotypes 6A and 19A in ug/mL.</description>
            <units>ug/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-6A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.38" lower_limit="0.33" upper_limit="0.44"/>
                  <measurement group_id="O2" value="0.48" lower_limit="0.36" upper_limit="0.63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-19A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.29" lower_limit="0.25" upper_limit="0.33"/>
                  <measurement group_id="O2" value="0.12" lower_limit="0.10" upper_limit="0.14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes</title>
        <description>The results were presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. In this assay the cut-off value for opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A was defined as &gt;= 8.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes</title>
            <description>The results were presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. In this assay the cut-off value for opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A was defined as &gt;= 8.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Opsono-6A (N=158; 60)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-19A (N= 162; 60)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations</title>
        <description>Concentration of anti-PRP antibody given as GMC in ug/mL.</description>
        <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="175"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentrations</title>
            <description>Concentration of anti-PRP antibody given as GMC in ug/mL.</description>
            <units>ug/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20.131" lower_limit="16.775" upper_limit="24.158"/>
                  <measurement group_id="O2" value="11.844" lower_limit="8.542" upper_limit="16.424"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Seroprotection Status Against PRP</title>
        <description>Seroprotection status is defined as anti-PRP antibody concentrations above 0.15 ug/mL and above 1.0 ug/mL</description>
        <time_frame>One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="175"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Seroprotection Status Against PRP</title>
            <description>Seroprotection status is defined as anti-PRP antibody concentrations above 0.15 ug/mL and above 1.0 ug/mL</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Above 0.15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="175"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Above 1.0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="173"/>
                  <measurement group_id="O2" value="58"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
        <time_frame>Within 4 days after each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="371"/>
                  <measurement group_id="O2" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Local Symptoms</title>
            <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="210"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="252"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="182"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include drowsiness, fever, irritability and loss of appetite.
Fever was defined as axillary temperature &gt;= 37.5 degrees Celsius.</description>
        <time_frame>Within 4 days after each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="371"/>
                  <measurement group_id="O2" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Solicited General Symptoms</title>
            <description>Solicited general symptoms assessed include drowsiness, fever, irritability and loss of appetite.
Fever was defined as axillary temperature &gt;= 37.5 degrees Celsius.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Drowsiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="113"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="293"/>
                  <measurement group_id="O2" value="99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Loss of Appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                  <measurement group_id="O2" value="66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
        <time_frame>Within 31 days after each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="374"/>
                  <measurement group_id="O2" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="213"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAE)</title>
        <description>An SAE is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>Following the administration of the first dose of the study vaccines throughout the entire study period up to study month 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="374"/>
                  <measurement group_id="O2" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Serious Adverse Events (SAE)</title>
            <description>An SAE is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to study Month 5</time_frame>
      <desc>Analysis was performed on the Total Vaccinated Cohort, on subjects with available data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Synflorix Group</title>
          <description>Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
        </group>
        <group group_id="E2">
          <title>Prevenar Group</title>
          <description>Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Croup infections</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="293" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="293" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>bronchiolitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
